Overview

Study Of Bupropion SR (323U66) In Patients With Major Depressive Disorder In Japan

Status:
Completed
Trial end date:
2007-11-01
Target enrollment:
Participant gender:
Summary
This is a study to obtain clinical experience of 323U66 SR for elderly patients with depression in repeat-dose of 323U66 SR up to 300mg/day, and to conduct exploratory investigation on safety, efficacy and pharmacokinetics profile in elderly patients with depression.
Phase:
Phase 2
Details
Lead Sponsor:
GlaxoSmithKline
Treatments:
Bupropion